Browsing Tag
Lupin Limited
41 posts
Big pharma shakeup: Lupin sells women’s health arm for mega millions
Lupin Limited, a global pharmaceutical leader, has officially divested its U.S. Commercial Women’s Health Specialty Business to Evofem…
Lupin Limited secures major victory: A perfect FDA score for its Gujarat plant
Lupin Limited (Lupin), a global pharmaceutical powerhouse, has been awarded the Establishment Inspection Report (EIR) by the United…
Lupin Limited appoints Abdelaziz Toumi as CEO of new subsidiary
Global pharmaceutical giant, Lupin Limited, announced the appointment of Abdelaziz Toumi (commonly known as Abdel) as the Chief…
Lupin Limited expands global specialty portfolio with strategic acquisitions
Global pharmaceutical leader Lupin Limited (Lupin) has announced the completion of a strategic acquisition through its European hub,…
Lupin Limited appoints Christoph Funke as Chief Technical Operations Officer to spearhead global pharmaceutical operations
Lupin Limited, a global leader in the pharmaceutical industry, announced today the strategic appointment of Christoph Funke to…
Lupin Limited secures FDA approval for generic Bromfenac Ophthalmic Solution
In a significant development for the global pharmaceutical industry, Lupin Limited (Lupin) has announced its latest achievement: receiving…
Lupin Limited announces satisfactory FDA inspection results for Mandideep facility
Global pharmaceutical major, Lupin Limited (Lupin), has announced receiving the Establishment Inspection Report (EIR) from the United States…
Can Lupin’s partnership with Caplin Steriles strengthen its position in the US injectable anesthetic market?
Lupin and Caplin Steriles secure FDA approval for generic Rocuronium Bromide Injection, targeting a $53M US anesthesia market segment.
Can Lupin’s clean FDA inspection at its Vizag API plant boost confidence in its global supply reliability?
Lupin’s Vizag API plant clears US FDA inspection with no observations, strengthening its US supply reliability and regulatory track record.
Lupin launches Lurasidone Hydrochloride in US, targeting $4.2bn bipolar depression market
Lupin launches Lurasidone Hydrochloride Tablets in the US, entering a $4.2B bipolar depression market with a full range of strengths.